Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07510841 | JY016 Injection in Patients With Advanced Solid Tumors Expressing EGFR | not yet recruiting | Phase 1 / Phase 2 | 228 | Biotech Pharmaceutical Co., Ltd.OTHER | 0 | Apr 6, 2026 | clinicaltrials |
| NCT02937272 | A Study of LY3200882 in Participants With Solid Tumors | active not recruiting | Phase 1 | 223 | Eli Lilly and CompanyINDUSTRY | 8 | Apr 3, 2026 | clinicaltrials |
| NCT05752552 |
| Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients With Advanced or Refractory Solid Tumours |
| recruiting |
| Phase 1 |
| 55 |
| DeuterOncologyINDUSTRY |
| 3 |
| Apr 3, 2026 |
| clinicaltrials |
| NCT07446153 | A Clinical Study of HRS-8364 in the Treatment of Advanced Solid Tumor Subjects | recruiting | Phase 1 / Phase 2 | 282 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Apr 3, 2026 | clinicaltrials |
| NCT04665206 | Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 434 | Vivace Therapeutics, IncINDUSTRY | 2 | Apr 2, 2026 | clinicaltrials |
| NCT05735080 | Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer(INX-315-01) | recruiting | Phase 1 / Phase 2 | 150 | Incyclix BioINDUSTRY | 2 | Apr 1, 2026 | clinicaltrials |
| NCT05773820 | A Study Explore WJB001 Capsules in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 210 | Wigen Biomedicine Technology (Shanghai) Co., Ltd.INDUSTRY | 1 | Apr 1, 2026 | clinicaltrials |
| NCT06770569 | A Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HRS-3802 Monotherapy in Patients With Malignant Solid Tumors | recruiting | Phase 1 | 100 | Shandong Suncadia Medicine Co., Ltd.INDUSTRY | 2 | Mar 30, 2026 | clinicaltrials |
| NCT05024214 | Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors | recruiting | Phase 1 / Phase 2 | 170 | 3D Medicines (Sichuan) Co., Ltd.INDUSTRY | 1 | Mar 25, 2026 | clinicaltrials |
| NCT07262164 | A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG2062 in Patients With Solid Tumors | recruiting | Phase 1 | 30 | Shanghai Virogin Biotech Co., Ltd.INDUSTRY | 1 | Mar 25, 2026 | clinicaltrials |
| NCT06781125 | One Trial of JCXH-211 Intratumoral Injection Combined With Anti-PD-1 Antibody in Patients With Malignant Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 72 | Immorna Biotherapeutics, Inc.INDUSTRY | 0 | Mar 24, 2026 | clinicaltrials |
| NCT07222969 | A Clinical Study to Evaluate the Safety of VIB305 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 146 | Vibrant Sciences LimitedINDUSTRY | 2 | Mar 23, 2026 | clinicaltrials |
| NCT07482319 | A Clinical Study GK01 Injection in Subjects With Advanced Malignant Solid Tumors | not yet recruiting | Phase 1 | 15 | Beijing Geekgene Technology Co., LTDINDUSTRY | 1 | Mar 23, 2026 | clinicaltrials |
| NCT02503423 | Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas | active not recruiting | Phase 1 / Phase 2 | 253 | Taiho Oncology, Inc.INDUSTRY | 8 | Mar 20, 2026 | clinicaltrials |
| NCT04419532 | A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 | 40 | Daiichi SankyoINDUSTRY | 3 | Mar 20, 2026 | clinicaltrials |
| NCT07229638 | A IB/II Phase Clinical Study on the Safety, Tolerability, and Efficacy of SHR-9839(sc) in Combination Anti-tumor Therapy in Patients With Solid Tumors | recruiting | Phase 1 / Phase 2 | 70 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Mar 20, 2026 | clinicaltrials |
| NCT02789228 | Research Study Utilizing Expanded Multi-antigen Specific Lymphocytes for the Treatment of Solid Tumors(REST) | active not recruiting | Phase 1 | 28 | Children's National Research InstituteOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT03478462 | Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas(CLOVER-2) | active not recruiting | Phase 1 | 30 | Cellectar Biosciences, Inc.INDUSTRY | 3 | Mar 18, 2026 | clinicaltrials |
| NCT04007744 | Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 36 | Mayo ClinicOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT04443088 | An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors(KEYNOTE-E12) | recruiting | Phase 1 | 78 | Shenzhen Ionova Life Sciences Co., Ltd.INDUSTRY | 1 | Mar 18, 2026 | clinicaltrials |
| NCT05101070 | S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors(aCCeleR8-001) | recruiting | Phase 1 / Phase 2 | 282 | ShionogiINDUSTRY | 2 | Mar 18, 2026 | clinicaltrials |
| NCT05689853 | Study of AK119 Combined With AK112 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 87 | AkesoINDUSTRY | 1 | Mar 18, 2026 | clinicaltrials |
| NCT06244771 | A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors(PROSPER) | recruiting | Phase 1 / Phase 2 | 403 | Frontier Medicines CorporationINDUSTRY | 3 | Mar 18, 2026 | clinicaltrials |
| NCT06804824 | A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 220 | Vividion Therapeutics, Inc.INDUSTRY | 2 | Mar 18, 2026 | clinicaltrials |
| NCT07479667 | An Antibody-armored Dendritic Cell in Patients With Solid Tumors(dendritic cell) | recruiting | Phase 1 | 8 | Shanghai Cell Therapy Group Co.,LtdINDUSTRY | 1 | Mar 18, 2026 | clinicaltrials |
| NCT04119024 | Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors | recruiting | Phase 1 | 18 | Anusha KalbasiOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT04802174 | Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers | active not recruiting | Phase 1 / Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | Mar 17, 2026 | clinicaltrials |
| NCT05888532 | 64Cu-GRIP B in Patients With Advanced Malignancies | recruiting | Phase 1 / Phase 2 | 91 | Rahul AggarwalOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT06736704 | SNV4818 in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 320 | Pikavation Therapeutics, Inc.INDUSTRY | 3 | Mar 13, 2026 | clinicaltrials |
| NCT06057922 | A Study YL201 in Patients With Selected Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 990 | MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Mar 12, 2026 | clinicaltrials |
| NCT07466160 | A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 280 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 1 | Mar 12, 2026 | clinicaltrials |
| NCT07035249 | DCSZ11 in Combination With Standard Therapy in Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 9 | West China HospitalOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT07417189 | A Phase I/II Study of ABSK141 in Patients With Advanced Solid Tumors ( ABSK141-101 ) | recruiting | Phase 1 / Phase 2 | 401 | Abbisko Therapeutics Co, LtdINDUSTRY | 1 | Mar 11, 2026 | clinicaltrials |
| NCT05781048 | A Phase I Clinical Study of the Safety， Tolerability，Pharmacokinetics, and Initial Efficacy of HRS-6209 Monotherapy in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 56 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Mar 10, 2026 | clinicaltrials |
| NCT07462442 | Study of QLS5308 in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 | 192 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Mar 10, 2026 | clinicaltrials |
| NCT04723810 | TumorGlow Intraoperative Molecular Imaging (IMI) | recruiting | Phase 1 / Phase 2 | 500 | University of PennsylvaniaOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT07069062 | A Phase I/Ⅱ Human Study of HY0001a for Injection in Adult Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 261 | Sichuan Huiyu Pharmaceutical Co., LtdINDUSTRY | 1 | Mar 9, 2026 | clinicaltrials |
| NCT05103631 | Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors | active not recruiting | Phase 1 | 12 | Baylor College of MedicineOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT05661201 | NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors | recruiting | Phase 1 | 24 | Georgetown UniversityOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT06171750 | Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors(ANCHOR) | recruiting | Phase 1 | 97 | Ankyra Therapeutics, IncINDUSTRY | 2 | Mar 6, 2026 | clinicaltrials |
| NCT07453394 | QLS5132 Combination Therapy in Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 626 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Mar 6, 2026 | clinicaltrials |
| NCT04900818 | Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 330 | I-Mab Biopharma US LimitedINDUSTRY | 2 | Mar 5, 2026 | clinicaltrials |
| NCT06667960 | Study of JK06 in Patients With Unresectable Locally Advanced or Metastatic Cancer | recruiting | Phase 1 / Phase 2 | 255 | Salubris Biotherapeutics IncINDUSTRY | 2 | Mar 5, 2026 | clinicaltrials |
| NCT07222631 | SB-4826 in Adult Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphomas | recruiting | Phase 1 / Phase 2 | 48 | University of California, San DiegoOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT06424665 | A Study of FZ-AD005 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 162 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.INDUSTRY | 1 | Mar 4, 2026 | clinicaltrials |
| NCT07304128 | A Study of PLB-002 in Advanced Solid Tumors | recruiting | Phase 1 | 100 | Primelink BioTherapeitics(ShenZhen) LimitedINDUSTRY | 1 | Mar 3, 2026 | clinicaltrials |
| NCT07446816 | A Clinical Study Evaluating the Preliminary Anti-tumor Efficacy and Safety of Hemay181 | recruiting | Phase 1 | 24 | Ganzhou Hemay Pharmaceutical Co., LtdINDUSTRY | 1 | Mar 3, 2026 | clinicaltrials |
| NCT06612645 | Safety and Efficacy of CMD03 CAR T Cell in Children With Relapse or Refractory Solid Tumors(CMD03) | recruiting | Phase 1 | 9 | Chulalongkorn UniversityOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT06715124 | QTX3544 in Patients With Advanced Solid Tumors With KRAS G12V Mutations | active not recruiting | Phase 1 | 237 | Quanta TherapeuticsINDUSTRY | 1 | Mar 2, 2026 | clinicaltrials |
| NCT07269080 | STM-06: POLARIS-POlymetastic Lesion Ablative Radiotherapy With Immunotherapy Study(STM-06) | recruiting | Phase 1 | 28 | University of Illinois at ChicagoOTHER | 1 | Mar 2, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Apr 6, 2026source: clinicaltrials